Singh, Sanminder
Kalb, Robert E.
de Jong, Elke M. G. J.
Shear, Neil H.
Lebwohl, Mark
Langholff, Wayne
Hopkins, Lori
Srivastava, Bhaskar
Armstrong, April W.
Article History
First Online: 28 September 2018
Compliance with Ethical Standards
:
: This study was supported by Janssen Scientific Affairs, LLC, Horsham, PA, USA.
: S. Singh has no conflicts of interest. R. E. Kalb has received grants and/or research funding from AbbVie, Amgen, Janssen, Merck & Co, Inc., and Novartis Pharmaceuticals Corp.; served as a consultant for Dermira, Janssen-Ortho, Inc., Regeneron, and Sun Pharmaceutical Industries, Ltd.; and was a member of a Data Safety Monitoring Board for Eli Lilly and Company. E.M.G.J. de Jong has received research grants for the independent research fund of the Dept. of Dermatology of the Radboud University Medical Center from AbbVie, Janssen, and Pfizer; and has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies manufacturing drugs for the treatment of psoriasis, including AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, and Pfizer (all funding goes to the independent research fund of “Radboud”). N. H. Shear has been a paid consultant for AbbVie, Actelion, Biogen, Celgene, Janssen, Leo, Lilly, Novartis, and Sanofi. M. Lebwohl is an employee of Mount Sinai, which receives research funds from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen/Johnson & Johnson, Kadmon, Medimmune/Astra Zeneca, Novartis, Pfizer, and ViDac. B. Srivastava and L. Hopkins are employees of Janssen Scientific Affairs, LLC, and W. Langholff is an employee of Janssen Research & Development, LLC. A.W. Armstrong has served as investigator, advisor, and/or consultant to AbbVie, Janssen, Novartis, Lilly, Regeneron, Sanofi, Leo, and Ortho Dermatologics.